FDA Approved: SENSIPAR — Supplemental Application (Amgen Inc)

View source ↗

Summary

The FDA approves a supplemental application for Sensipar (cinacalcet hydrochloride) submitted by Amgen Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercalcemia
• Hyperparathyroidism
• Parathyroid Carcinoma

Drugs mentioned

• SENSIPAR (CINACALCET HYDROCHLORIDE)

Snippet

SUPPL AP for SENSIPAR (CINACALCET HYDROCHLORIDE)